MedPage -- In premenopausal breast cancer patients, zoledronic acid (Zometa) was able to stave off chemotherapy-induced bone loss, investigators here found. Bone mineral density remained stable in patients who received the bisphosphonate drug during adjuvant chemotherapy, Dawn L. Hershman, M.D., of Columbia University here, and colleagues, reported online in the Journal of Clinical Oncology.
